PMID- 26352533
OWN - NLM
STAT- MEDLINE
DCOM- 20160920
LR  - 20220408
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 10
IP  - 11
DP  - 2015 Nov
TI  - EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as 
      Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
PG  - 1546-52
LID - 10.1097/JTO.0000000000000668 [doi]
AB  - INTRODUCTION: Reverse transcriptase polymerase chain reaction (RT-PCR) assay has 
      been proved to have high sensitivity and specificity to detect anaplastic 
      lymphoma kinase (ALK) rearrangements. The aim of this study was to investigate 
      the response to crizotinib in patients of advanced non-small-cell lung cancer 
      (NSCLC) with ALK rearrangements detected by RT-PCR. METHODS: Only patients with 
      advanced NSCLC who had their ALK rearrangement status detected by RT-PCR were 
      included in this analysis. The utility of RT-PCR and fluorescence in situ 
      hybridization (FISH) assay were compared in patients who were treated with 
      crizotinib based on their positive ALK rearrangements. RESULTS: One thousand ten 
      patients were included in this study. Among them, 104 patients were ALK RT-PCR 
      positive and 53 of them received crizotinib treatment. Among 255 tumors 
      simultaneously analyzed by FISH and RT-PCR, the latter successfully detected all 
      the 25 tumors with arrangements, including two cases that were missed by FISH. 
      The overall response rate and median progression-free survival of the 53 patients 
      with ALK rearrangements who received crizotinib treatment were 60.4% (95% 
      confidence interval [CI], 47.2-73.6) and 8.4 months (95% CI, 6.75-10.05), 
      respectively, which were similar to the 21 patients detected by FISH with overall 
      response rate of 57.1% (95% CI, 33.3-76.2; p = 0.799) and median progression-free 
      survival of 7.4 months (95% CI, 4.43-10.38; p = 0.833) after crizotinib 
      treatment. Interestingly, there were two patients responded to crizotinib had 
      their ALK rearrangement detected by RT-PCR but not FISH. CONCLUSIONS: RT-PCR 
      should be considered as an alternative/supplemental approach to detect ALK fusion 
      oncogene in NSCLC patients who might benefit from crizotinib treatment.
FAU - Wang, Yan
AU  - Wang Y
AD  - *Department of Medical Oncology, daggerDepartment of Laboratory Medicine, double daggerDepartment 
      of Lung Cancer and Immunology,  section signDepartment of Pathology, Shanghai Pulmonary 
      Hospital, Tongji University School of Medicine, Shanghai, China;  ||Department of 
      Hematology & Medical Oncology, Winship Cancer Institute, Emory University School 
      of Medicine, Georgia; and  paragraph signDivision of Hematology, Oncology and Blood & Marrow 
      Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer 
      Center, University of Iowa Carver College of Medicine, Iowa City, Iowa.
FAU - Zhang, Jun
AU  - Zhang J
FAU - Gao, Guanghui
AU  - Gao G
FAU - Li, Xuefei
AU  - Li X
FAU - Zhao, Chao
AU  - Zhao C
FAU - He, Yayi
AU  - He Y
FAU - Su, Chunxia
AU  - Su C
FAU - Zhang, Shijia
AU  - Zhang S
FAU - Chen, Xiaoxia
AU  - Chen X
FAU - Zhang, Jie
AU  - Zhang J
FAU - Li, Wei
AU  - Li W
FAU - Li, Bing
AU  - Li B
FAU - Zhao, Jing
AU  - Zhao J
FAU - Hou, Likun
AU  - Hou L
FAU - Wu, Chunyan
AU  - Wu C
FAU - Ren, Shengxiang
AU  - Ren S
FAU - Zhou, Caicun
AU  - Zhou C
FAU - Zhang, Jun
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Crizotinib
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics/*metabolism
MH  - Protein Kinase Inhibitors/administration & dosage/*therapeutic use
MH  - Pyrazoles/administration & dosage/*therapeutic use
MH  - Pyridines/administration & dosage/*therapeutic use
MH  - Reverse Transcriptase Polymerase Chain Reaction/*methods
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2015/09/10 06:00
MHDA- 2016/09/22 06:00
CRDT- 2015/09/10 06:00
PHST- 2015/09/10 06:00 [entrez]
PHST- 2015/09/10 06:00 [pubmed]
PHST- 2016/09/22 06:00 [medline]
AID - S1556-0864(15)35067-X [pii]
AID - 10.1097/JTO.0000000000000668 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2015 Nov;10(11):1546-52. doi: 10.1097/JTO.0000000000000668.